The threat of avian influenza A (H5N1). Part IV: development of vaccines

被引：38

作者：

Cinatl, Jindrich, Jr. ^{[1
]}

Michaelis, Martin ^{[1
]}

Doerr, Hans W. ^{[1
]}

机构：

[1] Hosp Johann Wolfgang Goethed Univ, Inst Med Virol, D-60596 Frankfurt, Germany

来源：

MEDICAL MICROBIOLOGY AND IMMUNOLOGY | 2007年 / 196卷 / 04期

关键词：

D O I：

10.1007/s00430-007-0052-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 are discussed. This fourth part focuses on vaccine development. Several phase I clinical studies with vaccines against H5 viruses have demonstrated limited efficacy compared to seasonal influenza vaccines. To induce protective immunity two immunisations with increased amounts of H5N1 vaccine were required. Novel vaccination strategies that are egg- and adjuvant-independent, broadly cross-reactive and long-lasting are highly desirable.

引用

页码：213 / 225

页数：13

共 105 条

[1]

Ada Gordon, 2003, Expert Opin Emerg Drugs, V8, P27, DOI 10.1517/eoed.8.1.27.21025

[2] Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs [J].

Alymova, IV ;

Kodihalli, S ;

Govorkova, EA ;

Fanget, B ;

Gerdil, C ;

Webster, RG .

JOURNAL OF VIROLOGY, 1998, 72 (05) :4472-4477

[3]

[Anonymous], 2006, Wkly Epidemiol Rec, V81, P328

[4] Current concepts - Avian influenza A (H5N1) infection in humans [J].

Beigel, H ;

Farrar, H ;

Han, AM ;

Hayden, FG ;

Hyer, R ;

de Jong, MD ;

Lochindarat, S ;

Tien, NTK ;

Hien, NT ;

Hien, TT ;

Nicoll, A ;

Touch, S ;

Yuen, KY .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1374-1385

[5] Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years [J].

Belshe, RB ;

Nichol, KL ;

Black, SB ;

Shinefield, H ;

Cordova, J ;

Walker, R ;

Hessel, C ;

Cho, I ;

Mendelman, PM .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) :920-927

[6] Live attenuated versus inactivated influenza vaccine in infants and young children [J].

Belshe, Robert B. ;

Edwards, Kathryn M. ;

Vesikari, Timo ;

Black, Steven V. ;

Walker, Robert E. ;

Hultquist, Micki ;

Kemble, George ;

Connor, Edward M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07) :685-696

[7] TRANSGENIC MICE LACKING CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED T-CELLS HAVE DELAYED VIRAL CLEARANCE AND INCREASED MORTALITY AFTER INFLUENZA-VIRUS CHALLENGE [J].

BENDER, BS ;

CROGHAN, T ;

ZHANG, LP ;

SMALL, PA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (04) :1143-1145

[8] INFLUENZA VIRUS-INFECTED DENDRITIC CELLS STIMULATE STRONG PROLIFERATIVE AND CYTOLYTIC RESPONSES FROM HUMAN CD8+ T-CELLS [J].

BHARDWAJ, N ;

BENDER, A ;

GONZALEZ, N ;

BUI, LK ;

GARRETT, MC ;

STEINMAN, RM .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (02) :797-807

[9] ANTIBODY-RESPONSE TO THE M2-PROTEIN OF INFLUENZA A-VIRUS EXPRESSED IN INSECT CELLS [J].

BLACK, RA ;

ROTA, PA ;

GORODKOVA, N ;

KLENK, HD ;

KENDAL, AP .

JOURNAL OF GENERAL VIROLOGY, 1993, 74 :143-146

[10] Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level [J].

Bracci, L ;

Canini, I ;

Puzelli, S ;

Sestili, P ;

Venditti, M ;

Spada, M ;

Donatelli, I ;

Belardelli, F ;

Proietti, E .

VACCINE, 2005, 23 (23) :2994-3004

← 1 2 3 4 5 6 7 8 9 10 →